Why Is Genus PLC Up Today?
Genus PLC shares rose 1.41% today, according to the market data provided, following a period of strong performance for the animal genetics specialist.
There is no single new announcement fully explaining today's move, but the Company's preliminary results for the year ended 30 June 2026, announced on 10 September 2026, showed significant strategic progress and a newly announced £60 million share buyback programme.
Genus has continued to attract attention following its disposal of 51% of PIC China, which generated a substantial one-off gain and provided the Group with a much-improved balance sheet.
Key Highlights
For the year ended 30 June 2026, Genus reported adjusted operating profit including joint ventures up 25% to £116.0 million, driven by strong PIC growth and a £5.6 million milestone payment from Chinese partner BCA.
Adjusted profit before tax rose 35% to £100.2 million, while statutory profit before tax surged to £310.5 million, largely reflecting a £204.1 million gain from the disposal of 51% of PIC China.
The Board announced a £60 million share buyback programme alongside an 11% increase in the final Dividend to 24.0p per share, taking the full-year dividend to 35.2p per share.
About Genus PLC
Genus PLC is a British-based animal genetics company, selling elite genetics and biotechnology-derived products to cattle and pig farmers worldwide.
The Group operates through Genus PIC (porcine genetics), Genus ABS (bovine genetics) and Genus Research and Development, with PIC's pedigree herds estimated to sire around 30% of commercially reared pigs globally.
Genus is headquartered in Basingstoke, Hampshire, and is a constituent of the FTSE 250 Index, with operations spanning North America, Latin America, the UK, Europe, the Middle East, Russia, Africa and Asia.
Key Reasons Behind Today's Rise
Today's 1.41% gain reflects continued positive sentiment following Genus's record FY26 preliminary results, which showed strong profit growth alongside a significant reduction in leverage.
The newly announced £60 million share buyback programme signals management confidence in the Group's cash generation and Balance Sheet strength following the PIC China transaction.
Genus's Leverage has fallen significantly to 0.4x, supported by free Cash Flow generation up 52% to £62.0 million, providing additional financial flexibility.
PIC China Joint Venture And Strategic Progress
Genus completed the disposal of 51% of PIC China, forming a strategic porcine joint venture that generated a £204.1 million gain and materially strengthened the Group's balance sheet.
PIC China Royalty revenue has grown by more than 50%, with the Business winning around 25 new customers over two years, underscoring the strategic value of Genus's genetics technology in the Chinese pork market.
The Group also received further global regulatory approvals for its pioneering PRP gene edit, a technology aimed at improving disease resilience in pig herds, which management views as an important Long-term Growth driver.
Growth Catalysts
The clearest catalyst for Genus is continued royalty Revenue growth from PIC China, alongside further regulatory approvals and commercial rollout of its PRP gene edit technology.
Continued Value Acceleration Programme benefits at Genus ABS, its bovine genetics business, could support further Margin improvement across the Group.
A reduced leverage position following the PIC China transaction provides Genus with greater flexibility for further M&A, Buybacks or reinvestment in its genetics research pipeline.
Risks
For FY27, Genus expects resilient but moderate profit growth, reflecting cyclical weakness including first-half disease-related challenges in North American pork production and low pork prices in Brazil.
Subdued global dairy prices could weigh on the performance of Genus ABS, the Group's bovine genetics business, over the coming year.
As an agricultural biotechnology company, Genus remains exposed to livestock disease outbreaks, Commodity price cycles and regulatory approval timelines for its gene editing technologies.
Wider Market Backdrop
Global agricultural markets have faced a mixed backdrop over the past year, with broader macroeconomic uncertainty, including Middle East-related energy price volatility, feeding into input cost pressures for livestock producers globally.
Genus's exposure to structural growth in global protein demand, alongside genetics-driven productivity gains, has provided some insulation from shorter-term agricultural commodity cycles.
A stabilisation in global pork and dairy prices would likely support faster growth for Genus's underlying customer base, indirectly benefiting royalty and product sales.
Valuation
Genus shares have performed strongly over the past year, supported by record profits, a strengthened balance sheet, and the newly announced share buyback programme.
With basic earnings per share up 35% to 110.3p on an adjusted basis for FY26, and statutory EPS surging due to the PIC China gain, the Group's valuation reflects genuine underlying earnings momentum.
Analysts including Deutsche Bank and Investec have maintained Buy ratings on Genus, with price targets in the region of 3,000-3,300p, implying continued confidence in the growth outlook.
What Investors Should Watch Next
Investors should watch PIC China royalty revenue growth and further customer wins as a key indicator of the joint venture's ongoing success.
Progress on PRP gene edit regulatory approvals and commercial rollout will be important for the Group's longer-term growth story.
FY27 profit trends, particularly recovery from North American disease-related challenges and Brazilian pork pricing, will be worth monitoring closely.
Conclusion
Genus has delivered a transformative year, combining record Underlying Profit growth with a strategically important PIC China transaction that has strengthened its balance sheet substantially.
Today's 1.41% rise reflects continued positive sentiment following these preliminary results and the newly announced £60 million buyback programme.
The key question ahead will be whether Genus can sustain its growth momentum through FY27's more cyclically challenging conditions in North American pork and global dairy markets.






Please wait processing your request...